SB 190 would require most Kentucky health benefit plans that cover hospital, medical, or surgical expenses to include coverage for up to 20 visits of chronic pain treatments per event. Covered services would include treatments provided by licensed professionals in acupuncture, chiropractic care, chronic pain management, hyperbaric oxygen therapy, massage therapy, occupational therapy, osteopathic manipulation, physical therapy, or psychotherapy. The bill also allows an insured person to seek these services without first obtaining a referral from a health care provider, and it limits cost-sharing so that deductibles, coinsurance, and copays for these treatments cannot exceed those for a primary care visit.
The bill also amends Kentucky Medicaid law to require the Department for Medicaid Services, managed care organizations, and the state medical assistance program to comply with the new chronic pain treatment coverage requirement, subject to any needed federal approval. In addition, it changes controlled-substance prescribing rules by requiring practitioners, before initially prescribing or dispensing certain Schedule II drugs or hydrocodone-containing Schedule III drugs, to discuss and refer or prescribe chronic pain treatments when appropriate. The bill preserves existing opioid-prescribing requirements and clarifies that it does not require all non-opioid chronic pain treatments to be exhausted before an opioid prescription may be issued.
SB 190 appears to be a health-care access and opioid-alternatives measure, with the overall structure suggesting support for expanding non-opioid pain management options. The bill’s effective date is January 1, 2027, and the private insurance coverage mandate would apply to plans issued or renewed on or after that date. Its Medicaid provisions would take effect only if necessary federal authorization is obtained, and the bill directs the Cabinet for Health and Family Services or the Department for Medicaid Services to seek that approval within 90 days if needed.
Because there were no recorded committee transcripts or votes in the provided material, there is no documented floor or committee debate to indicate a formal sentiment breakdown. Based on the bill text alone, the main policy emphasis is on expanding access to chronic pain treatments and encouraging non-opioid alternatives, while preserving clinical judgment and not making those therapies a prerequisite to opioid prescribing. The principal likely point of contention is the cost and mandate impact on insurers and Medicaid, as well as whether the required referral/discussion language could affect prescribing practices or create administrative burdens for providers.
SB 190 would create a new insurance coverage mandate in Kentucky law for chronic pain treatments and would incorporate that mandate into Medicaid administration through KRS 205.522. It also amends Kentucky’s controlled-substance prescribing framework in KRS 218A.172 to require practitioners to discuss and, when appropriate, refer or prescribe chronic pain treatment options before initial prescribing of certain opioids. The bill affects private insurers, Medicaid managed care organizations, health care providers, and patients seeking pain treatment, while preserving existing opioid-prescribing safeguards and allowing for federal approval before Medicaid implementation if required.
No committee discussion or vote record was provided, so there is no direct evidence of support or opposition from legislators in the available materials. The bill’s text suggests a generally pro-access, pro-nonopioid-treatment policy approach, aimed at expanding chronic pain care options and reducing reliance on opioids where clinically appropriate. At the same time, the inclusion of explicit carveouts and a statement that non-opioid treatments need not be exhausted before opioid prescribing indicates an effort to balance pain-management expansion with provider discretion.
The most likely areas of contention are the insurance mandate and its cost implications, especially for health plans and Medicaid programs that would have to cover 20 visits per event for multiple therapy types. Providers and insurers may also scrutinize the requirement that practitioners discuss and refer or prescribe chronic pain treatments before initial opioid prescribing, though the bill softens this by making the action dependent on clinical judgment and treatment availability. Another possible issue is implementation for Medicaid, since federal approval may be needed to avoid loss of federal funds, and the bill allows delay only for provisions requiring that approval.